Provocative Strategies for Primary PCI in STEMI: Time to Rethink Guidelines

Main Article Content

Rameez Akhtar
Muhammad Adil
Shakeel Akhtar
Nusrum Iqbal
Farhan Shahzad

Abstract

Background: The primary percutaneous coronary intervention (PCI) is now the reference treatment for ST-segment elevation myocardial infarction (STEMI). Findings from randomized controlled trials suggest that PCI is superior to thrombolytic therapy in preventing death and recurrent myocardial infarction. However, longer delays for PCI implementation and variability in outcomes among different operators and centers may affect its efficacy. The European guidelines recommend fibrinolytic therapy if PCI cannot be performed within 120 minutes of the first medical contact.


Objective: The main objective of the study was to evaluate the efficacy of adjunctive provocative strategies in primary PCI for STEMI and their impact on procedural success and clinical outcomes.


Methods: This retrospective observational study was conducted at Luqman International Hospital, Mingora Swat, from December 2022 to June 2023. Data were collected from 230 STEMI patients, including demographic information, clinical characteristics, procedural details, and outcomes. The primary outcome measure was the occurrence of major adverse cardiac events (MACE) within 30 days and one year after primary PCI. Secondary outcomes included procedural success rate, myocardial blush grade, and left ventricular ejection fraction (LVEF) during follow-up assessments. Statistical analyses were performed using SPSS version 25, with continuous variables expressed as means and standard deviations and categorical variables as frequencies and percentages. Comparisons between groups were conducted using chi-square tests for categorical variables and Student’s t-tests or Mann-Whitney U tests for continuous variables, with a p-value of less than 0.05 considered statistically significant.


Results: Of the 230 patients, 120 (52%) received conventional strategies, while 110 (48%) received adjunctive provocative strategies. The provocative strategy group had higher rates of successful reperfusion (95.5% vs. 83.3%), improved myocardial blush grades (mean ± SD: 3.2 ± 0.6 vs. 2.7 ± 0.8), and lower rates of the no-reflow phenomenon (9.1% vs. 20.8%). At 30 days post-PCI, the incidence of MACE was lower in the provocative strategy group (9.1% vs. 12.5%). At one year, the provocative strategy group continued to show lower MACE rates (16.4% vs. 20.8%).


Conclusion: Adjunctive provocative strategies in primary PCI for STEMI show promise in enhancing reperfusion efficacy and preserving myocardial function. While trends towards improved procedural success and short-term outcomes were observed, larger prospective studies are needed to validate these findings. The exploration of provocative strategies represents an important avenue for advancing STEMI management and improving patient outcomes in interventional cardiology.

Article Details

How to Cite
Akhtar, R., Adil, M., Akhtar, S., Iqbal, N., & Shahzad, F. (2024). Provocative Strategies for Primary PCI in STEMI: Time to Rethink Guidelines. Journal of Health and Rehabilitation Research, 4(2), 1166–1170. https://doi.org/10.61919/jhrr.v4i2.1032
Section
Articles
Author Biographies

Rameez Akhtar, Luqman International Hospital Mingora Swat Pakistan.

Medical Director, Cardiology Department, Luqman International Hospital Mingora Swat, Pakistan.

Muhammad Adil, MTI Lady Reading Hospital Peshawar Pakistan.

Associate Professor, Cardiology Department, MTI Lady Reading Hospital Peshawar, Pakistan.

Shakeel Akhtar, Cardiology Department, BKMC/GKMC, Swabi

Medical Officer, Cardiology Department, BKMC/GKMC, Swabi

Nusrum Iqbal, MD Health Center Lahore Pakistan.

Chairman, Department of Internal Medicine, MD Health Center, Lahore Pakistan.

Farhan Shahzad, Aga Khan University Karachi Pakistan.

Alumni School of Nursing and Midwifery, Aga Khan University Karachi, Pakistan.

References

Alyamani M, Campbell S, Navarese E, Welsh RC, Bainey KR. Safety and Efficacy of Intracoronary Thrombolysis as Adjunctive Therapy to Primary PCI in STEMI: A Systematic Review and Meta-Analysis. Can J Cardiol. 2021;37(2):339-46.

Frampton J, Devries JT, Welch TD, Gersh BJ. Modern Management of ST-Segment Elevation Myocardial Infarction. Curr Probl Cardiol. 2020;45(3):100393.

Gue YX, Kanji R, Gati S, Gorog DA. MI With Non-Obstructive Coronary Artery Presenting With STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. Eur Cardiol Rev. 2020;15.

Winiger A, Rodgers GP. Acute Coronary Syndrome (ACS) ST Segment Elevation Myocardial Infarction. In: Cardiovascular Manual for the Advanced Practice Provider: Mastering the Basics. Cham: Springer International Publishing; 2023. p. 21-30.

Hu MJ, Tan JS, Jiang WY, Gao XJ, Yang YJ. The Optimal Percutaneous Coronary Intervention Strategy for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Pairwise and Network Meta-Analysis. Ther Adv Chronic Dis. 2022;13:20406223221078088.

Lüscher TF. Frontiers of Acute Coronary Syndromes: Primary PCI Time Window, 15-Year Outcomes, Bleeding and MINOCA. Eur Heart J. 2020;41(7):805-9.

Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2020;5(8):881-8.

Kumar J, Kumar R, Armstrong R, Murphy R, Daly C. Incidence and Prevalence of MINOCA (Myocardial Infarction With Non-Obstructive Coronary Arteries) in STEMI Patients: Experience From Irish Tertiary Care Centre. 2021.

Barthélémy O, Jobs A, Meliga E, Mueller C, Rutten FH, Siontis GC, et al. Questions and Answers on Workup Diagnosis and Risk Stratification: A Companion Document of the 2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Eur Heart J. 2021;42(14):1379-86.

Rallidis LS, Xenogiannis I, Brilakis ES, Bhatt DL. Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(24):2431-9.

Rumiz E, Vilar JV, Cubillos A, Valero E, Berenguer A, Fácila L, et al. Long-Term Recurrent Events in ST-Elevation Myocardial Infarction and Multivessel Disease: The Impact of Different Revascularization Strategies. Rev Port Cardiol. 2023;42(5):445-51.

Takahashi K, Takemoto M, Sakaue T, Ikeda S, Okura T. Vasospasm in the First Septal Perforator Branch and Late High-Grade Atrioventricular Block Following Successful Primary Percutaneous Coronary Intervention for the Proximal Left Anterior Descending Coronary Artery: A Case Report. Cureus. 2023;15(5).

Saito Y, Oyama K, Tsujita K, Yasuda S, Kobayashi Y. Treatment Strategies of Acute Myocardial Infarction: Updates on Revascularization, Pharmacological Therapy, and Beyond. J Cardiol. 2023;81(2):168-78.

Figini F, Chen SL, Sheiban I. ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease–A Critical Review of Current Practice, Evidence and Meta-Analyses. Heart Int. 2020;14(2):80.

Bainey KR, Marquis-Gravel G, Mehta SR, Tanguay JF. The Evolution of Anticoagulation for Percutaneous Coronary Intervention: A 40-Year Journey. Can J Cardiol. 2022;38(10).

Lancellotti P, Petitjean H, Nchimi A, Cosyns B. Special Issue on Ischemic Heart Disease. Acta Cardiol. 2023;78(1):1-4.

Hong MK. Contrast-Induced Nephropathy During Primary Percutaneous Coronary Intervention: Are We Helping the Patients With the Diagnosis or Merely Treating the Laboratory Values?. American Journal of Cardiology. 2023 Sep 15;203:488-9.

Roffi M. What Is New in the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes. Cardiol Discov. 2023;3(04):227-31.

Hong MK. Contrast-Induced Nephropathy During Primary Percutaneous Coronary Intervention: Are We Helping the Patients With the Diagnosis or Merely Treating the Laboratory Values?. Am J Cardiol. 2023;203:488-9.

Civieri G, Kerkhof PL, Montisci R, Iliceto S, Tona F. Sex differences in diagnostic modalities of coronary artery disease: Evidence from coronary microcirculation. Atherosclerosis. 2023 Sep 27:117276.

Most read articles by the same author(s)